Genentech Licenses Alector’s Brain-Penetrant Parkinson’s Drug for $1.27B
Genentech has acquired exclusive global rights to Alector’s preclinical Parkinson’s candidate, AL050, in a deal worth up to $1.27 billion. The agreement includes a $100 million upfront payment and extends Alector’s cash runway to 2029.